The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium–glucose cotransporter 2 inhibitor

The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium–glucose cotransporter 2 inhibitor

Abstract Background Sodium–glucose cotransporter 2 inhibitor (SGLT2i) use reduces body weight (BW) in patients with type 2 diabetes mellitus (T2DM). Obesity and T2DM are strong risk factors of new-onset atrial fibrillation (AF). However, whether BW loss following SGLT2i treatment reduces AF risk in...

Full description

Bibliographic Details
Main Authors: Yi-Hsin Chan, Shao-Wei Chen, Tze-Fan Chao, Yi-Wei Kao, Chien-Ying Huang, Pao-Hsien Chu
Format: Article
Language:English
Published: BMC 2021-04-01
Series:Cardiovascular Diabetology
Subjects:
Atrial fibrillation
Type 2 diabetes mellitus
Sodium–glucose cotransporter-2 inhibitor
Heart failure
Obesity
Online Access:https://doi.org/10.1186/s12933-021-01285-8

Similar Items

Similar Items